The influence of pretransplant interferon-α therapy on survival after allogenous BMT in patients with CML.

被引：0
|
作者：
Hochhaus, A [1 ]
Kolb, HJ [1 ]
Hasford, J [1 ]
Berger, U [1 ]
Muth, A [1 ]
Pfirrmann, M [1 ]
Hehlmann, R [1 ]
机构：
[1] Univ Heidelberg, Klinikum Mannheim, Med Klin, Mannheim, Germany
来源：
BONE MARROW TRANSPLANTATION | 1999年 / 23卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
191
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [1] Survival after allogenous bone marrow transplantation in patients with chronic myeloid leukemia (CML) is not influenced by pretransplant interferon α therapy
    Hehlmann, R
    Hochhaus, A
    Berger, U
    Muth, A
    Kolb, HJ
    Pfirrmann, M
    Hasford, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 317 - 317
  • [2] Life-threatening immune pancytopenia after mud BMT for CML.
    Onida, F
    Pozzoli, E
    Tagliaferri, E
    Annaloro, C
    Della Volpe, A
    Deliliers, GL
    BONE MARROW TRANSPLANTATION, 1998, 21 : S33 - S33
  • [3] Successful bone marrow engrafment after third BMT in accelerated phase CML.
    Manna, A
    Rizzo, C
    Cervellera, M
    Maggi, A
    Barcaglione, P
    Amurri, B
    Palazzo, G
    Mazza, P
    Bacigalupo, A
    BONE MARROW TRANSPLANTATION, 1998, 21 : S81 - S81
  • [4] Influence of pretransplant treatment on survival after allogeneous bone marrow transplantation in CML
    Hehlmann, R
    Kolb, HJ
    Berger, U
    Muth, A
    Hochhaus, A
    Ansari, H
    BLOOD, 1997, 90 (10) : 1005 - 1005
  • [5] GM-CSF improves activity of interferon as primary therapy for CML.
    Smith, BD
    Matsui, WH
    Murphy, K
    Gladstone, DE
    Jones, RJ
    BLOOD, 2004, 104 (11) : 253B - 253B
  • [6] The outcome of allogenous bone marrow transplantation is strongly influenced by early discontinuation of interferon-α pretreatment in patients with chronic myeloid leukemia (CML).
    Hochhaus, A
    Hehlmann, R
    Kolb, HJ
    Muth, A
    Pfirrmann, M
    Holler, E
    Berger, U
    Hasford, J
    BLOOD, 1998, 92 (10) : 495A - 495A
  • [7] Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy
    Martinelli, G
    Testoni, N
    Amabile, M
    Bonifazi, F
    De Vivo, A
    Farabegoli, P
    Terragna, C
    Montefusco, V
    Ottaviani, E
    Saglio, G
    Russo, D
    Baccarani, M
    Rosti, G
    Tura, S
    BONE MARROW TRANSPLANTATION, 2000, 25 (07) : 729 - 736
  • [8] Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy
    G Martinelli
    N Testoni
    M Amabile
    F Bonifazi
    A De Vivo
    P Farabegoli
    C Terragna
    V Montefusco
    E Ottaviani
    G Saglio
    D Russo
    M Baccarani
    G Rosti
    S Tura
    Bone Marrow Transplantation, 2000, 25 : 729 - 736
  • [9] Thyrotoxicosis after interferon-α therapy
    Csaki, AC
    Blum, M
    THYROID, 2000, 10 (01) : 101 - 101
  • [10] Significance of quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α based therapy.
    Martinelli, G
    Testoni, N
    Amabile, M
    Bonifazi, F
    Farabegoli, P
    Terragna, C
    Montefusco, V
    Ottaviani, E
    Saglio, G
    Russo, D
    Baccarani, M
    Rosti, G
    Tura, S
    BLOOD, 1998, 92 (10) : 368B - 368B
12345